Health Condition 1: C539- Malignant neoplasm of cervix uteri, unspecified Health Condition 2: C14- Malignant neoplasm of other and ill-defined sites in the lip, oral cavity and pharynx
Conditions
Interventions
Intervention1: Not Applicable: Not Applicable
Control Intervention1: Not Applicable: Not Applicable
Sponsors
Medical Research Council University College London
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients with: a. Histologically confirmed head and neck cancers of the oropharynx, larynx, hypopharynx, and nasopharynx (American Joint Committee on Cancer (AJCC) Stage I to IVB) that have given consent for radical radiotherapy (with or without concurrent chemotherapy). Patients can be included if they have had induction chemotherapy prior to radiotherapy. OR b. Histologically confirmed primary cervical cancer (International Federation of Gynaecology and Obstetrics (FIGO)/AJCC Stage IB to IIIC1) that have given consent for radical radiotherapy (with or without concurrent chemotherapy). Patients can be included if they have had induction chemotherapy prior to radiotherapy. OR c. Histologically confirmed primary prostate cancer (AJCC Stage I to IVB) that have given consent for radical radiotherapy. Patients can be included if they have had prior chemotherapy or are taking a hormonal therapy for their prostate cancer. 2. Provide signed informed consent to participate in the study.3. Aged greater than or equal to 18 years.
Exclusion criteria
Exclusion criteria: 1. Patients requiring radiotherapy after curative surgery or surgery that is intended to remove as much of the tumor as possible. 2. Patients receiving a palliative dose of radiotherapy. 3. Patients that have any metal implants within the treatment field e.g. hip prostheses. Dental implants are acceptable.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall treatment plan acceptability Plan acceptability between the manual plan and that generated by automated treatment planningTimepoint: 4 years | — |
Secondary
| Measure | Time frame |
|---|---|
| Time and resource savings Timepoint: 4 years;Cost effectiveness Timepoint: 4 years | — |
Countries
India, Jordan, Malaysia, South Africa
Contacts
Public ContactDr Sarbani Ghosh Laskar
Tata Memorial Hospital
Outcome results
None listed